Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R. Gandara, David S. Shames, Geoff Otto et al.|Nature Medicine|2018Cited by 1.2k
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Salvatore Siena et al.|The Lancet Oncology|2019Cited by 537
BRAF Inhibition in <i>BRAF</i> <sup>V600</sup> -Mutant Gliomas: Results From the VE-BASKET StudyThomas Kaley, David M. Hyman, Mehdi Touat et al.|Journal of Clinical Oncology|2018Cited by 330
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapySusan O’Brien, Michael J. Keating, Farhad Ravandi et al.|Blood|2007Cited by 89